v3.26.1
Cover - shares
 6 Months Ended
Mar. 31, 2026
Jun. 10, 2026
Document Information [Line Items]    
Document Type 10-Q/A  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag true  
Amendment Description This Amendment No. 1 on Form 10-Q/A (this “Amended Report”) amends the Quarterly Report on Form 10-Q of NeuroOne Medical Technologies Corporation (the “Company,” “we,” “our,” or “us”) for the quarterly period ended March 31, 2026, originally filed with the Securities and Exchange Commission (“SEC”) on May 12, 2026 (the “Original Filing”). This Amended Report is being filed to restate the Company’s unaudited condensed financial statements and related disclosures for the three and six months ended March 31, 2026, as described in Note 2, “Restatement of Previously Issued Unaudited Condensed Financial Statements,” to the unaudited condensed financial statements included herein. Information that was not affected by the restatement is unchanged from the Original Filing.Restatement Background.Subsequent to filing the Original Filing, the Company identified errors in product revenue and cost of product revenue recognition related to modified purchase orders accounted for under ASC 606. The errors resulted from the duplication of product revenue and cost of product revenue recognized during the three months ended March 31, 2026. As a result, revenue and gross profit was overstated by an aggregate amount of $529 thousand and $296 thousand, respectively, for the three and six months ended March 31, 2026. In addition, the accounts receivable was overstated by $529 thousand and inventory was understated by $233 thousand as a result of the errors.Management evaluated the errors in accordance with ASC 250, Accounting Changes and Error Corrections, and Staff Accounting Bulletin No. 99 and No. 108, and concluded that the errors were material to the previously issued interim financial statements as of and for the three and six months ended March 31, 2026. The errors did not result from intentional misconduct and were attributable to a process control deficiency in customer purchase order tracking.The Company is implementing enhanced reconciliation and review controls designed to prevent similar errors in future reporting periods.Items Amended.The following items of the Original Filing have been amended and restated:Part I, Item 1: Financial Statements (Unaudited) — including the condensed balance sheet as of March 31, 2026, the condensed statements of operations for the three and six months ended March 31, 2026, the condensed statements of stockholders’ equity for the three and six months ended March 31, 2026, the condensed statement of cash flows for the six months ended March 31, 2026, and the related notes to the unaudited condensed consolidated financial statements.Part I, Item 2: Management’s Discussion and Analysis of Financial Condition and Results of OperationsPart I, Item 4: Controls and ProceduresPart II, Item 1A: Risk FactorsPart II, Item 6: ExhibitsIn addition, the Company’s Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this Form 10-Q/A (Exhibits 31.1, 31.2 and 32).Except as described above, no other items of the Original Filing have been amended. This Amended Report does not reflect events occurring after the date of the Original Filing or modify or update those disclosures in any way, other than as required to reflect the effects of the restatement. Accordingly, this Amended Report should be read in conjunction with the Company’s filings with the SEC subsequent to the date of the Original Filing.  
Document Period End Date Mar. 31, 2026  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q2  
Entity Information [Line Items]    
Entity Registrant Name NeuroOne Medical Technologies Corporation  
Entity Central Index Key 0001500198  
Entity File Number 001-40439  
Entity Tax Identification Number 27-0863354  
Entity Incorporation, State or Country Code DE  
Current Fiscal Year End Date --09-30  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One 7599 Anagram Drive  
Entity Address, City or Town Eden Prairie  
Entity Address, State or Province MN  
Entity Address, Postal Zip Code 55344  
Entity Phone Fax Numbers [Line Items]    
City Area Code 952  
Local Phone Number 426-1383  
Entity Listings [Line Items]    
Title of 12(b) Security Common stock, $0.001 par value  
Trading Symbol NMTC  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   8,702,982